Advertisement

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients

  • A. Cabré
    Correspondence
    Corresponding author at: Unitat de Recerca de Lípids i Arteriosclerosi, Facultat de Medicina i Ciències de la Salut, C.Sant Llorenç 21, 43201 Reus, Spain. Tel.: +34 977759367; fax: +34 977759322.
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • I. Lázaro
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • J. Girona
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • J.M. Manzanares
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • F. Marimón
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • N. Plana
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • M. Heras
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author
  • L. Masana
    Affiliations
    Research Unit on Lipids and Atherosclerosis, Faculty of Medicine and Health Sciences, IRCIS, Department of Internal Medicine, Sant Joan University Hospital, Reus, Spain
    Search for articles by this author

      Abstract

      Objective

      To study the role of FABP4 in the plasma of type 2 diabetic (T2D) subjects with and without metabolic syndrome (MS) and the impact of thiazolidinedione (TZD) treatment.

      Methods and results

      FABP4 was analyzed in 274 individuals (169 T2D subjects and 105 controls). MS-T2D subjects had higher FABP4 levels than non-MS-T2D subjects and controls (53% and 76% increase, respectively, p < 0.005). FABP4 levels in T2D subjects were positively correlated to the number of MS elements, obesity degree, adiponectin, triglycerides, lipoperoxides, C-reactive protein, age, systolic blood pressure and diabetes duration (p < 0.05). Neither clinical or subclinical atherosclerosis, nor plasma levels of insulin, glucose or RBP4 were associated to FABP4. TZD-treated T2D subjects showed > 30% higher FABP4 levels (p < 0.05) than non-TZD-treated T2D. A subgroup study confirmed that TZD treatment prospectively increased FABP4 levels (p < 0.05) along with an increase of peripheral blood mononuclear cell PPARγ activity (p < 0.05). Furthermore, in vitro studies showed that TZD treatment increased FABP4 mRNA, intracellular protein levels and extracellular secretion from human adipocytes.

      Conclusions/interpretation

      FABP4 plasma concentrations are increased with the early presence of MS components, as well as inflammation and oxidation markers in T2D subjects. TZD increases FABP4 plasma concentrations, reflecting PPARγ activation. FABP4 plasma measurements could be useful in the management of T2D subjects.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Singh B.
        • Mallika V.
        • Goswami B.
        Metabolic syndrome: diagnosis, potential markers and management-an update.
        Clin Chim Acta. 2007; 380: 4-12
        • Kahn R.
        • Buse J.
        • Ferrannini E.
        • Stern M.
        The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2005; 28: 2289-2304
        • Kershaw E.E.
        • Flier J.S.
        Adipose tissue as an endocrine organ.
        J Clin Endocrinol Metab. 2004; 89: 2548-2556
        • Trayhurn P.
        • Wood I.S.
        Adipokines: inflammation and the pleiotropic role of white adipose tissue.
        Br J Nutr. 2004; 92: 347-355
        • Xu A.
        • Wang Y.
        • Xu J.Y.
        • et al.
        Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome.
        Clin Chem. 2006; 52: 405-413
        • Stejskal D.
        • Karpisek M.
        Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?.
        Eur J Clin Invest. 2006; 36: 621-625
        • Boord J.B.
        • Fazio S.
        • Linton M.F.
        Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis.
        Curr Opin Lipidol. 2002; 13: 141-147
        • Distel R.J.
        • Robinson G.S.
        • Spiegelman B.M.
        Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms.
        J Biol Chem. 1992; 267: 5937-5941
        • Pelton P.D.
        • Zhou L.
        • Demarest K.T.
        • Burris T.P.
        PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes.
        Biochem Biophys Res Commun. 1999; 261: 456-458
        • Melki S.A.
        • Abumrad N.A.
        Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation.
        J Lipid Res. 1993; 34: 1527-1534
        • Boord J.B.
        • Maeda K.
        • Makowski L.
        • et al.
        Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice.
        Circulation. 2004; 110: 1492-1498
        • Makowski L.
        • Brittingham K.C.
        • Reynolds J.M.
        • Suttles J.
        • Hotamisligil G.S.
        The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities.
        J Biol Chem. 2005; 280: 12888-12895
        • Perera R.J.
        • Marcusson E.G.
        • Koo S.
        • et al.
        Identification of novel PPARgamma target genes in primary human adipocytes.
        Gene. 2006; 369: 90-99
        • Fu Y.
        • Luo N.
        • Lopes-Virella M.F.
        Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages.
        J Lipid Res. 2000; 41: 2017-2023
        • Fu Y.
        • Luo N.
        • Lopes-Virella M.F.
        • Garvey W.T.
        The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages.
        Atherosclerosis. 2002; 165: 259-269
        • Fu Y.
        • Luo L.
        • Luo N.
        • Garvey W.T.
        Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages.
        Atherosclerosis. 2006; 188: 102-111
        • Makowski L.
        • Boord J.B.
        • Maeda K.
        • et al.
        Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis.
        Nat Med. 2001; 7: 699-705
        • Peters A.L.
        • Schriger D.L.
        The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors.
        Am J Med. 1998; 105: 15S-19S
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Ohlsson B.G.
        • Englund M.C.
        • Karlsson A.L.
        • et al.
        Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappaB to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages.
        J Clin Invest. 1996; 98: 78-89
        • Livak K.J.
        • Schmittgen T.D.
        Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.
        Methods. 2001; 25: 402-408
        • Xu A.
        • Tso A.W.
        • Cheung B.M.
        • et al.
        Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study.
        Circulation. 2007; 115: 1537-1543
        • Xu H.
        • Barnes G.T.
        • Yang Q.
        • et al.
        Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
        J Clin Invest. 2003; 112: 1821-1830
        • Scheja L.
        • Makowski L.
        • Uysal K.T.
        • et al.
        Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice.
        Diabetes. 1999; 48: 1987-1994
        • Maeda K.
        • Cao H.
        • Kono K.
        • et al.
        Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes.
        Cell Metab. 2005; 1: 107-119
        • Graham T.E.
        • Yang Q.
        • Bluher M.
        • et al.
        Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.
        N Engl J Med. 2006; 354: 2552-2563
        • Cho Y.M.
        • Youn B.S.
        • Lee H.
        • et al.
        Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes.
        Diabetes Care. 2006; 29: 2457-2461
        • Kantartzis K.
        • Rittig K.
        • Balletshofer B.
        • et al.
        The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity.
        Clin Chem. 2006; 52: 1934-1942
        • Tuncman G.
        • Erbay E.
        • Hom X.
        • et al.
        A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease.
        Proc Natl Acad Sci USA. 2006; 103: 6970-6975
        • Schachtrup C.
        • Emmler T.
        • Bleck B.
        • Sandqvist A.
        • Spener F.
        Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins.
        Biochem J. 2004; 382: 239-245
        • Coort S.L.
        • Coumans W.A.
        • Bonen A.
        • et al.
        Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats.
        J Lipid Res. 2005; 46: 1295-1302